{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:19:31Z","timestamp":1792783171840,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Beijing Life Oasis Public Service Center","award":["No. BH004506"],"award-info":[{"award-number":["No. BH004506"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-11651-y","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T07:42:39Z","timestamp":1777102959000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Fibromodulin positively regulated by Androgen Receptor, promotes prostate cancer progression via the PI3K\/AKT signaling pathway and epithelial-medenchymal transition"],"prefix":"10.1007","volume":"53","author":[{"given":"Jingzhe","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danfeng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenjie","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuesheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,25]]},"reference":[{"key":"11651_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74:229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"11651_CR2","doi-asserted-by":"publisher","first-page":"a030452","DOI":"10.1101\/cshperspect.a030452","volume":"7","author":"C Dai","year":"2017","unstructured":"Dai C, Heemers H, Sharifi N (2017) Androgen signaling in prostate cancer. Cold Spring Harbor Perspect Med 7(9):a030452. https:\/\/doi.org\/10.1101\/cshperspect.a030452","journal-title":"Cold Spring Harbor Perspect Med"},{"issue":"17","key":"11651_CR3","doi-asserted-by":"publisher","first-page":"5730","DOI":"10.3390\/molecules27175730","volume":"27","author":"M Sekhoacha","year":"2022","unstructured":"Sekhoacha M, Riet K, Motloung P, Gumenku L, Adegoke A, Mashele S (2022) Prostate cancer review: genetics, diagnosis, treatment options, and alternative approaches. Molecules 27(17):5730. https:\/\/doi.org\/10.3390\/molecules27175730","journal-title":"Molecules"},{"key":"11651_CR4","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/ju.0000000000003491","volume":"210","author":"JT Wei","year":"2023","unstructured":"Wei JT, Barocas D, Carlsson S, Coakley F, Eggener S, Etzioni R et al (2023) Early Detection of prostate cancer: AUA\/SUO guideline part I: prostate cancer screening. J Urol 210:46\u201353. https:\/\/doi.org\/10.1097\/ju.0000000000003491","journal-title":"J Urol"},{"key":"11651_CR5","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3109\/10409239709108551","volume":"32","author":"RV Iozzo","year":"1997","unstructured":"Iozzo RV (1997) The family of the small leucine-rich proteoglycans: key regulators of matrix assembly and cellular growth. Crit Rev Biochem Mol Biol 32:141\u2013174. https:\/\/doi.org\/10.3109\/10409239709108551","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"11651_CR6","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1177\/00220345221138525","volume":"102","author":"Z Zheng","year":"2023","unstructured":"Zheng Z, Granado HS, Li C (2023) Fibromodulin, a multifunctional matricellular modulator. J Dent Res 102:125\u2013134. https:\/\/doi.org\/10.1177\/00220345221138525","journal-title":"J Dent Res"},{"key":"11651_CR7","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12935-019-0870-6","volume":"19","author":"MH Pourhanifeh","year":"2019","unstructured":"Pourhanifeh MH, Mohammadi R, Noruzi S, Hosseini SA, Fanoudi S, Mohamadi Y et al (2019) The role of fibromodulin in cancer pathogenesis: implications for diagnosis and therapy. Cancer Cell Int 19:157. https:\/\/doi.org\/10.1186\/s12935-019-0870-6","journal-title":"Cancer Cell Int"},{"key":"11651_CR8","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/j.1365-2141.2010.08362.x","volume":"151","author":"A Choudhury","year":"2010","unstructured":"Choudhury A, Derkow K, Daneshmanesh AH, Mikaelsson E, Kiaii S, Kokhaei P et al (2010) Silencing of ROR1 and FMOD with siRNA results in apoptosis of CLL cells. Br J Haematol 151:327\u2013335. https:\/\/doi.org\/10.1111\/j.1365-2141.2010.08362.x","journal-title":"Br J Haematol"},{"key":"11651_CR9","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.3389\/fphar.2019.01308","volume":"10","author":"FU Khan","year":"2019","unstructured":"Khan FU, Owusu-Tieku NYG, Dai X, Liu K, Wu Y, Tsai HI et al (2019) Wnt\/\u03b2-catenin pathway-regulated fibromodulin expression is crucial for breast cancer metastasis and inhibited by aspirin. Front Pharmacol 10:1308. https:\/\/doi.org\/10.3389\/fphar.2019.01308","journal-title":"Front Pharmacol"},{"issue":"3","key":"11651_CR10","doi-asserted-by":"publisher","first-page":"944","DOI":"10.3390\/pharmaceutics15030944","volume":"15","author":"T Deng","year":"2023","unstructured":"Deng T, Hou Y, Lin G, Feng C, Liu K, Chen W et al (2023) A novel fibromodulin antagonist peptide RP4 exerts antitumor effects on colorectal cancer. Pharmaceutics 15(3):944. https:\/\/doi.org\/10.3390\/pharmaceutics15030944","journal-title":"Pharmaceutics"},{"key":"11651_CR11","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1186\/s12885-024-12783-9","volume":"24","author":"Y Xiao","year":"2024","unstructured":"Xiao Y, Lai C, Hu J, Mulati Y, Xu X, Luo J et al (2024) Integrative analysis regarding the correlation between collagen-related genes and prostate cancer. BMC Cancer 24:1038. https:\/\/doi.org\/10.1186\/s12885-024-12783-9","journal-title":"BMC Cancer"},{"key":"11651_CR12","doi-asserted-by":"publisher","first-page":"1166668","DOI":"10.3389\/fgene.2023.1166668","volume":"14","author":"X Liu","year":"2023","unstructured":"Liu X, Wang K (2023) Development of a novel, clinically relevant anoikis-related gene signature to forecast prognosis in patients with prostate cancer. Front Genet 14:1166668. https:\/\/doi.org\/10.3389\/fgene.2023.1166668","journal-title":"Front Genet"},{"key":"11651_CR13","doi-asserted-by":"publisher","first-page":"120046","DOI":"10.1016\/j.lfs.2021.120046","volume":"286","author":"S Zhu","year":"2021","unstructured":"Zhu S, Jiao W, Xu Y, Hou L, Li H, Shao J et al (2021) Palmitic acid inhibits prostate cancer cell proliferation and metastasis by suppressing the PI3K\/Akt pathway. Life Sci 286:120046. https:\/\/doi.org\/10.1016\/j.lfs.2021.120046","journal-title":"Life Sci"},{"key":"11651_CR14","doi-asserted-by":"publisher","first-page":"e70354","DOI":"10.1002\/cam4.70354","volume":"13","author":"R Wang","year":"2024","unstructured":"Wang R, Qu Z, Lv Y, Yao L, Qian Y, Zhang X et al (2024) Important roles of PI3K\/AKT signaling pathway and relevant inhibitors in prostate cancer progression. Cancer Med 13:e70354. https:\/\/doi.org\/10.1002\/cam4.70354","journal-title":"Cancer Med"},{"issue":"3","key":"11651_CR15","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.3390\/ijms24032046","volume":"24","author":"E Tortorella","year":"2023","unstructured":"Tortorella E, Giantulli S, Sciarra A, Silvestri I, AR (2023) PI3K\/AKT in prostate cancer: a tale of two interconnected pathways. Int J Mol Sci 24(3):2046. https:\/\/doi.org\/10.3390\/ijms24032046","journal-title":"Int J Mol Sci"},{"key":"11651_CR16","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1172\/jci132031","volume":"130","author":"J Mateo","year":"2020","unstructured":"Mateo J, Seed G, Bertan C, Rescigno P, Dolling D, Figueiredo I et al (2020) Genomics of lethal prostate cancer at diagnosis and castration resistance. J Clin Invest 130:1743\u20131751. https:\/\/doi.org\/10.1172\/jci132031","journal-title":"J Clin Invest"},{"key":"11651_CR17","unstructured":"Tumor Immune Estimation Resource (2024) https:\/\/cistrome.shinyapps.io\/timer\/. Accessed 21 July"},{"key":"11651_CR18","unstructured":"National Center of Biotechnology Information (2024) https:\/\/www.ncbi.nlm.nih.gov\/. Accessed 18 March"},{"key":"11651_CR19","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s44446-025-00056-w","volume":"34","author":"S Alobid","year":"2026","unstructured":"Alobid S (2026) Targeting the PI3K\/AKT\/mTOR signaling pathway in prostate cancer: Molecular dysregulation, therapeutic advances, and future directions. Saudi Pharm J 34:2. https:\/\/doi.org\/10.1007\/s44446-025-00056-w","journal-title":"Saudi Pharm J"},{"key":"11651_CR20","unstructured":"JASPER (2024) https:\/\/jaspar.elixir.no\/. Accessed 5 September"},{"key":"11651_CR21","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A (2024) Cancer statistics, 2024. CA Cancer J Clin 74:12\u201349. https:\/\/doi.org\/10.3322\/caac.21820","journal-title":"CA Cancer J Clin"},{"issue":"21","key":"11651_CR22","doi-asserted-by":"publisher","first-page":"5417","DOI":"10.3390\/cancers13215417","volume":"13","author":"A Jacob","year":"2021","unstructured":"Jacob A, Raj R, Allison DB, Myint ZW (2021) Androgen receptor signaling in prostate cancer and therapeutic strategies. Cancers 13(21):5417. https:\/\/doi.org\/10.3390\/cancers13215417","journal-title":"Cancers"},{"key":"11651_CR23","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/nrurol.2017.144","volume":"14","author":"V Murillo-Garz\u00f3n","year":"2017","unstructured":"Murillo-Garz\u00f3n V, Kypta R (2017) WNT signalling in prostate cancer. Nat Rev Urol 14:683\u2013696. https:\/\/doi.org\/10.1038\/nrurol.2017.144","journal-title":"Nat Rev Urol"},{"issue":"20","key":"11651_CR24","doi-asserted-by":"publisher","first-page":"4969","DOI":"10.3390\/cancers15204969","volume":"15","author":"MA Hussein","year":"2023","unstructured":"Hussein MA, Munirathinam G (2023) Androgen receptor signaling in prostate cancer genomic subtypes. Cancers 15(20):4969. https:\/\/doi.org\/10.3390\/cancers15204969","journal-title":"Cancers"},{"issue":"2","key":"11651_CR25","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3390\/cells13020191","volume":"13","author":"LE Lumahan","year":"2024","unstructured":"Lumahan LE, Arif M, Whitener AE, Yi P (2024) Regulating androgen receptor function in prostate cancer: exploring the diversity of post-translational modifications. Cells 13(2):191. https:\/\/doi.org\/10.3390\/cells13020191","journal-title":"Cells"},{"issue":"5","key":"11651_CR26","doi-asserted-by":"publisher","first-page":"898","DOI":"10.3390\/cells11050898","volume":"11","author":"D \u00d6zturan","year":"2022","unstructured":"\u00d6zturan D, Morova T, Lack NA (2022) Androgen receptor-mediated transcription in prostate cancer. Cells 11(5):898. https:\/\/doi.org\/10.3390\/cells11050898","journal-title":"Cells"},{"key":"11651_CR27","doi-asserted-by":"publisher","first-page":"5501","DOI":"10.1038\/onc.2013.206","volume":"32","author":"T Karantanos","year":"2013","unstructured":"Karantanos T, Corn PG, Thompson TC (2013) Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene 32:5501\u20135511. https:\/\/doi.org\/10.1038\/onc.2013.206","journal-title":"Oncogene"},{"issue":"20","key":"11651_CR28","doi-asserted-by":"publisher","first-page":"5047","DOI":"10.3390\/cancers15205047","volume":"15","author":"TK Le","year":"2023","unstructured":"Le TK, Duong QH, Baylot V, Fargette C, Baboudjian M, Colleaux L et al (2023) Castration-resistant prostate cancer: from uncovered resistance mechanisms to current treatments. Cancers 15(20):5047. https:\/\/doi.org\/10.3390\/cancers15205047","journal-title":"Cancers"},{"key":"11651_CR29","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.2217\/fon-2023-0227","volume":"19","author":"Y Yu","year":"2023","unstructured":"Yu Y, Papukashvili D, Ren R, Rcheulishvili N, Feng S, Bai W et al (2023) siRNA-based approaches for castration-resistant prostate cancer therapy targeting the androgen receptor signaling pathway. Future Oncol 19:2055\u20132073. https:\/\/doi.org\/10.2217\/fon-2023-0227","journal-title":"Future Oncol"},{"key":"11651_CR30","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/bju.13123","volume":"117","author":"J Schalken","year":"2016","unstructured":"Schalken J, Fitzpatrick JM (2016) Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer. BJU Int 117:215\u2013225. https:\/\/doi.org\/10.1111\/bju.13123","journal-title":"BJU Int"},{"key":"11651_CR31","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ccell.2019.01.008","volume":"35","author":"L Cato","year":"2019","unstructured":"Cato L, de Tribolet-Hardy J, Lee I, Rottenberg JT, Coleman I, Melchers D et al (2019) ARv7 represses tumor-suppressor genes in castration-resistant prostate cancer. Cancer Cell 35:401\u201313e6. https:\/\/doi.org\/10.1016\/j.ccell.2019.01.008","journal-title":"Cancer Cell"},{"issue":"7","key":"11651_CR32","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.3390\/cancers13071534","volume":"13","author":"M Ehsani","year":"2021","unstructured":"Ehsani M, David FO, Baniahmad A (2021) Androgen receptor-dependent mechanisms mediating drug resistance in prostate cancer. Cancers 13(7):1534. https:\/\/doi.org\/10.3390\/cancers13071534","journal-title":"Cancers"},{"key":"11651_CR33","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1038\/onc.2017.385","volume":"37","author":"W Han","year":"2018","unstructured":"Han W, Gao S, Barrett D, Ahmed M, Han D, Macoska JA et al (2018) Reactivation of androgen receptor-regulated lipid biosynthesis drives the progression of castration-resistant prostate cancer. Oncogene 37:710\u2013721. https:\/\/doi.org\/10.1038\/onc.2017.385","journal-title":"Oncogene"},{"key":"11651_CR34","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.trecan.2020.04.010","volume":"6","author":"U Swami","year":"2020","unstructured":"Swami U, McFarland TR, Nussenzveig R, Agarwal N (2020) Advanced prostate cancer: treatment advances and future directions. Trends Cancer 6:702\u2013715. https:\/\/doi.org\/10.1016\/j.trecan.2020.04.010","journal-title":"Trends Cancer"},{"key":"11651_CR35","doi-asserted-by":"publisher","first-page":"e0201422","DOI":"10.1371\/journal.pone.0201422","volume":"13","author":"K Anden\u00e6s","year":"2018","unstructured":"Anden\u00e6s K, Lunde IG, Mohammadzadeh N, Dahl CP, Aronsen JM, Strand ME et al (2018) The extracellular matrix proteoglycan fibromodulin is upregulated in clinical and experimental heart failure and affects cardiac remodeling. PLoS ONE 13:e0201422. https:\/\/doi.org\/10.1371\/journal.pone.0201422","journal-title":"PLoS ONE"},{"issue":"8","key":"11651_CR36","doi-asserted-by":"publisher","first-page":"864","DOI":"10.3390\/cells8080864","volume":"8","author":"Z Chen","year":"2019","unstructured":"Chen Z, Song X, Li Q, Xie L, Guo T, Su T et al (2019) Androgen receptor-activated enhancers simultaneously regulate oncogene TMPRSS2 and lncRNA PRCAT38 in prostate cancer. Cells 8(8):864. https:\/\/doi.org\/10.3390\/cells8080864","journal-title":"Cells"},{"key":"11651_CR37","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1158\/0008-5472.Can-08-3760","volume":"69","author":"JC Pignon","year":"2009","unstructured":"Pignon JC, Koopmansch B, Nolens G, Delacroix L, Waltregny D, Winkler R (2009) Androgen receptor controls EGFR and ERBB2 gene expression at different levels in prostate cancer cell lines. Cancer Res 69:2941\u20132949. https:\/\/doi.org\/10.1158\/0008-5472.Can-08-3760","journal-title":"Cancer Res"},{"key":"11651_CR38","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1177\/1535370214531880","volume":"239","author":"M Chu","year":"2014","unstructured":"Chu M, Chang Y, Wang N, Li W, Li P, Gao WQ (2014) Hypermethylation-mediated transcriptional repression of TMPRSS2 in androgen receptor-negative prostate cancer cells. Exp Biol Med (Maywood) 239:823\u2013828. https:\/\/doi.org\/10.1177\/1535370214531880","journal-title":"Exp Biol Med (Maywood)"},{"issue":"14","key":"11651_CR39","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.3390\/cancers15143549","volume":"15","author":"A Berdiaki","year":"2023","unstructured":"Berdiaki A, Giatagana EM, Tzanakakis G, Nikitovic D (2023) The landscape of small leucine-rich proteoglycan impact on cancer pathogenesis with a focus on biglycan and lumican. Cancers 15(14):3549. https:\/\/doi.org\/10.3390\/cancers15143549","journal-title":"Cancers"},{"key":"11651_CR40","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.3389\/fonc.2020.01488","volume":"10","author":"I Bourgot","year":"2020","unstructured":"Bourgot I, Primac I, Louis T, No\u00ebl A, Maquoi E (2020) Reciprocal interplay between fibrillar collagens and collagen-binding integrins: implications in cancer progression and metastasis. Front Oncol 10:1488. https:\/\/doi.org\/10.3389\/fonc.2020.01488","journal-title":"Front Oncol"},{"issue":"6","key":"11651_CR41","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.3390\/cancers15061899","volume":"15","author":"K Wright","year":"2023","unstructured":"Wright K, Ly T, Kriet M, Czirok A, Thomas SM (2023) Cancer-associated fibroblasts: master tumor microenvironment modifiers. Cancers 15(6):1899. https:\/\/doi.org\/10.3390\/cancers15061899","journal-title":"Cancers"},{"key":"11651_CR42","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12943-023-01744-8","volume":"22","author":"Z Yuan","year":"2023","unstructured":"Yuan Z, Li Y, Zhang S, Wang X, Dou H, Yu X et al (2023) Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments. Mol Cancer 22:48. https:\/\/doi.org\/10.1186\/s12943-023-01744-8","journal-title":"Mol Cancer"},{"key":"11651_CR43","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nrurol.2018.9","volume":"15","author":"T Jamaspishvili","year":"2018","unstructured":"Jamaspishvili T, Berman DM, Ross AE, Scher HI, De Marzo AM, Squire JA et al (2018) Clinical implications of PTEN loss in prostate cancer. Nat Rev Urol 15:222\u2013234. https:\/\/doi.org\/10.1038\/nrurol.2018.9","journal-title":"Nat Rev Urol"},{"key":"11651_CR44","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s12079-022-00702-1","volume":"17","author":"M Hashemi","year":"2023","unstructured":"Hashemi M, Taheriazam A, Daneii P, Hassanpour A, Kakavand A, Rezaei S et al (2023) Targeting PI3K\/Akt signaling in prostate cancer therapy. J Cell Commun Signal 17:423\u2013443. https:\/\/doi.org\/10.1007\/s12079-022-00702-1","journal-title":"J Cell Commun Signal"},{"issue":"11","key":"11651_CR45","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.3390\/cells9112342","volume":"9","author":"DJ Turnham","year":"2020","unstructured":"Turnham DJ, Bullock N, Dass MS, Staffurth JN, Pearson HB (2020) The PTEN conundrum: how to target PTEN-deficient prostate cancer. Cells 9(11):2342. https:\/\/doi.org\/10.3390\/cells9112342","journal-title":"Cells"},{"key":"11651_CR46","doi-asserted-by":"publisher","first-page":"D1670","DOI":"10.1093\/nar\/gkae973","volume":"53","author":"S Jiang","year":"2025","unstructured":"Jiang S, Li H, Zhang L, Mu W, Zhang Y, Chen T et al (2025) Generic Diagramming Platform (GDP): a comprehensive database of high-quality biomedical graphics. Nucleic Acids Res 53:D1670\u2013d6. https:\/\/doi.org\/10.1093\/nar\/gkae973","journal-title":"Nucleic Acids Res"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11651-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-11651-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11651-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T07:42:40Z","timestamp":1777102960000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-11651-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,25]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["11651"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-11651-y","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,25]]},"assertion":[{"value":"2 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All authors have endorsed the work and concur with its submission to Cellular Signalling.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent from the patient for publication"}},{"value":"All methods were sanctioned by the Institutional Animal Care and Use Committee of Shandong Provincial Hospital (Ethics No. 2024-0032).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Statement"}}],"article-number":"669"}}